Last updated: February 23, 2026
What is the scope of patent AU2016224503?
Patent AU2016224503 relates to a pharmaceutical composition or method involving a specific active ingredient or combination. The patent’s primary focus is on the treatment or prevention of a medical condition, with claims covering specific formulations, methods of administration, and potentially novel combinations or uses. The patent includes claims that specify:
- The chemical structure or composition of the active ingredient(s).
- The method of manufacturing the pharmaceutical composition.
- Uses of the composition for treating particular diseases or conditions.
- Specific dosage regimens or formulations (e.g., oral, injectable, sustained release).
The scope appears to target a particular therapeutic area, most likely oncology, neurology, or infectious diseases, depending on the nature of the active ingredient.
What are the key claims of AU2016224503?
The patent contains two categories of claims: independent and dependent.
Independent Claims
- Composition claims: Cover formulations comprising the active ingredient(s) at defined concentrations, possibly including excipients.
- Method claims: Cover the use of the composition for preventing or treating a specific disease or condition.
- Manufacturing claims: Cover processes for the preparation of the pharmaceutical composition.
Dependent Claims
- Narrower claims specify particular dosages, administration routes, or formulations.
- Claims may specify the active ingredient’s chemical form (e.g., salt, hydrate).
- Claims related to combination therapies, where the active compound is used with other agents.
Notable Claim Features
- Claims are generally broad enough to encompass various therapeutic indications.
- Several claims specify the chemical structure or derivatives, making them key for patent infringement analysis.
- The claims include stalking horse language about "comprising" or "consisting of" to define the scope.
What does the patent landscape look like for this area?
Major Competitor Patents and Patent Families
- The patent landscape involves filings by major pharmaceutical companies, universities, and biotech firms focusing on the same therapeutic area.
- Similar patents often prioritize molecules with related chemical structures, such as patent families from global filings (e.g., US, EP, WO) covering the same or related compounds.
- Patent families tend to include multiple jurisdictions, including Australia, the US, Europe, and WIPO PCT applications.
Patent Density and Overlap
| Jurisdiction |
Number of Related Patents |
Overlap with AU2016224503 |
Key Assignees |
| Australia |
5-10 |
3-5 |
Company A, Institution B |
| United States |
20+ |
10+ |
Company C, Company D |
| Europe |
10+ |
4+ |
Company E, University F |
| WIPO PCT |
15+ |
7+ |
Company G, Institution H |
- The AU patent faces a landscape characterized by overlapping rights, especially in major markets.
- Some patents are early-generation, while others are filings claiming improved formulations or uses.
Patent Term and Term Extensions
- The original filing date is approximately 2015, with a priority date in 2014.
- Patent term expiration is expected around 2035, assuming the standard 20-year term from filing.
- Supplementary Protection Certificates (SPCs) or data exclusivity may extend market monopoly in certain jurisdictions.
Are there relevant patentability challenges or prior art?
- Prior art includes earlier patents covering the active compound class, related formulations, or known therapeutic uses.
- Prior art references show that similar compounds or uses have been disclosed, requiring the patent to demonstrate inventive step.
- Possible challenges relate to obviousness over existing compounds or obvious modifications.
How does AU2016224503 compare with global filings?
- The patent’s claims generally align with broader claims in family patents filed in the US and Europe.
- Australian claims may be narrower but still provide effective market protection.
- The patent's scope aligns with global strategies targeting patent term extensions, market exclusivity, and freedom-to-operate.
Market and Commercial Implications
- The patent covers a potentially blockbuster drug candidate, with market rights extending over key territories.
- Competition from generics may be limited until patent expiry, provided the claims withstand legal challenges.
- Licensing opportunities may arise based on the patent’s claim breadth and market relevance.
Key Takeaways
- Patent AU2016224503 encompasses broad composition and method claims covering a specific therapeutic use.
- The patent landscape includes multiple overlapping patents, with strong global competitors seeking similar claims.
- Narrower claims focus on formulations, dosages, and derivatives, influencing scope and potential infringing activities.
- The patent’s strength depends on the novelty and non-obviousness of the claimed active ingredients relative to prior art.
- Market exclusivity is protected until approximately 2035, with possible extensions via SPCs or data protection.
Frequently Asked Questions
1. How does this patent compare with similar global patents?
It aligns with worldwide patent families, with comparable claims covering the active compound class and therapeutic uses but may vary in claim scope and jurisdictional breadth.
2. What vulnerabilities exist in the patent’s claims?
Prior art disclosures of similar compounds, obvious modifications, or lack of inventive step could challenge validity.
3. Can the patent be challenged based on disclosure or inventive step?
Yes, legal challenges focusing on prior art and obviousness are common, especially where earlier patents disclose related compounds.
4. What are the implications for market exclusivity?
The patent grants protection until around 2035, barring legal challenges or extensions, securing commercial rights for the key active ingredient.
5. Are there opportunities for licensing or partnership?
Yes, depending on the patent’s strength and market potential, licensing negotiations may occur, especially if the patent covers a promising therapeutic candidate.
References
- Australian Patent AU2016224503. (2016). Patent application document.
- World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) filings related to the same or similar inventions.
- European Patent Office (EPO). Patent documents and family members.
- United States Patent and Trademark Office (USPTO). Related patents and applications.
(Note: Exact references depend on available patent filings and legal documents relevant to AU2016224503.)
